参芪肝康片联合肝动脉栓塞化疗治疗中晚期肝细胞癌的疗效及对栓塞后综合征的影响  

Efficacy of Shenqi Gankang Tablet combined with transcatheter arterial chemoembolization in the treatment of moderate and advanced hepatocellular carcinoma and its impact on post-embolization syndrome

作　　者：黄迁祥 高鹏 徐振皓 朱帝文[2] 贺晓娜 王亚杰 HUANG Qian-xiang;GAO Peng;XU Zhen-hao;ZHU Di-wen;HE Xiao-na;WANG Ya-jie(Department of Interventional Vascular Surgery,Xuchang People's Hospital,Xuchang 461000,Henan,CHINA;Department of Interventional Radiology,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,Xinjiang,CHINA)

机构地区：[1]许昌市人民医院介入血管科,河南许昌461000 [2]新疆医科大学第一附属医院介入放射科,新疆乌鲁木齐830000

出　　处：《海南医学》2025年第4期466-471,共6页Hainan Medical Journal

基　　金：新疆天山英才医药卫生高层次人才培养计划项目(编号:TSYC202301B032)。

摘　　要：目的探究参芪肝康片联合肝动脉栓塞化疗(TACE)治疗中晚期肝细胞癌的疗效及对栓塞后综合征的影响。方法选取2023年2月至2024年1月许昌市人民医院收治的120例中晚期肝细胞癌患者作为研究对象,按随机数表法分为对照组和观察组各60例。对照组患者采用TACE治疗,术后予以常规治疗,观察组于此基础上加用参芪肝康片治疗,21 d为一个疗程,共6个疗程。比较两组患者的疗效,以及治疗前后的肝功能[谷草转氨酶(ST)、谷丙转氨酶(LT)、总胆红素(TBil)]、肿瘤标志物[α-L-岩藻糖苷酶(FU)、高尔基蛋白73(GP73)、甲胎蛋白异质体3(FP-L3)]和免疫指标CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+),同时比较两组患者术后3 d和术后两周的栓塞后综合征和治疗期间的不良反应发生情况。结果治疗6个疗程后,观察组患者的总有效率为66.67%,明显高于对照组的40.00%,差异有统计学意义(P<0.05);观察组患者治疗3个疗程、6个疗程后的血清ALT、AST和TBil水平明显低于对照组,差异均有统计学意义(P<0.05);观察组患者治疗3个疗程、6个疗程后的GP73、FU和FP-L3水平明显低于对照组,差异均有统计学意义(P<0.05);观察组患者治疗3、6个月后CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)水平明显高于对照组,差异均有统计学意义(P<0.05);观察组患者术后两周的恶心呕吐、肝区疼痛、乏力发生率分别为16.67%、13.33%、10.00%,明显低于对照组的46.67%、43.33%、25.00%,差异均有统计学意义(P<0.05);治疗期间,两组患者的不良反应比较差异无统计学意义(P>0.05)。结论参芪肝康片联合TACE治疗中晚期肝细胞癌能有效减轻患者的肝损害,改善肝功能,降低肝癌标志物水平及栓塞后综合征风险,疗效确切且安全性较高。Objective To explore the efficacy of Shenqi Gankang Tablet combined with transcatheter arterial chemoembolization(TACE)in the treatment of moderate and advanced hepatocellular carcinoma and its impact on post-embolization syndrome.Methods A total of 120 patients with moderate and advanced hepatocellular carcinoma admitted to Xuchang People's Hospital from February 2023 to January 2024 were selected as the research subjects,and they were randomly divided into a control group and an observation group according to a random number table method,with 60 patients in each group.Patients in the control group underwent TACE treatment and conventional treatment after surgery,while those in the observation group were treated additionally with Shenqi Gankang Tablet on this basis,for 6 courses of treatment,with 21 days as one course of treatment.The efficacy between the two groups was compared,as well as liver function(glutamic oxaloacetic transaminase[ST],glutamic pyruvic transaminase[LT],total bilirubin[TBil]),tumor markers(α-L-fucosidase[FU],Golgi protein 73[GP73],alpha-fetoprotein variant 3[FP-L3]),immune in-dicators CD4^(+),CD3^(+),CD4^(+)/CD8^(+)before and after treatment.The occurrence of post-embolization syndrome and adverse reactions during treatment were also compared between the two groups of patients at 3 d postoperatively and 2 weeks postoperatively.Results After 6 months of treatment,the total effective rate of the observation group was 66.67%,which was significantly higher than 40.00%of the control group(P<0.05).The levels of serum ALT,AST,and TBil in the observation group after 3 and 6 courses of treatment were significantly lower than those in the control group(P<0.05).The levels of GP73,FU,and FP-L3 in the observation group after 3 and 6 courses of treatment were significantly lower than those in the control group(P<0.05).The levels of CD4^(+),CD3^(+),and CD4^(+)/CD8^(+)in the observation group were significantly higher than those in the control group after 3 and 6 months of treatment(P<0.05).The incidence

关 键 词：肝细胞癌 肝动脉栓塞化疗 参芪肝康片 栓塞后综合征 肿瘤标志物 疗效 

分 类 号：R735.7[医药卫生—肿瘤]